Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
Delayed Quote. Delayed Nyse - 07/17 04:01:29 pm
68.32 USD   -1.21%
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15ALLERGAN : Form 8.3 -
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AbbVie : Alphabet-Backed Calico Pledge Another $1 Billion to Age-Related Partnership

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/26/2018 | 08:56am EDT

By Colin Kellaher

AbbVie and Calico, a life-science company backed by Google parent Alphabet, on Tuesday said they will each invest an additional $500 million to extend their collaboration on new therapies for patients with age-related diseases, including neurodegeneration and cancer.

The companies said Calico, led by former Genentech Chairman and Chief Executive Arthur Levinson, will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027.

AbbVie, the North Chicago, Ill., biopharmaceutical company, will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.

The companies said they will share costs and profits equally.

Google and AbbVie launched the initial $1.5 billion partnership in 2014.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE -1.21% 68.32 Delayed Quote.-25.89%
ALPHABET -0.58% 1146.74 Delayed Quote.10.38%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
07/16ABBVIE INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15ALLERGAN : Form 8.3 -
DJ
07/15ABBVIE : Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
PR
07/12ABBVIE : Ex-dividend day for
FA
07/11ALLERGAN : Form 8.3 -
DJ
07/11ABBVIE : to Host Second-Quarter 2019 Earnings Conference Call
PR
07/10ABBVIE : Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
PR
07/09ABBVIE : Initial filing by director officer or owner of more than ten percent.
PU
More news
Financials (USD)
Sales 2019 32 941 M
EBIT 2019 15 564 M
Net income 2019 10 755 M
Debt 2019 31 154 M
Yield 2019 6,20%
P/E ratio 2019 9,33x
P/E ratio 2020 8,32x
EV / Sales2019 4,01x
EV / Sales2020 3,50x
Capitalization 101 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 87,00  $
Last Close Price 68,32  $
Spread / Highest target 68,3%
Spread / Average Target 27,3%
Spread / Lowest Target 6,85%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Senior Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-25.89%101 002
JOHNSON & JOHNSON2.67%372 000
PFIZER-1.83%238 617
ROCHE HOLDING LTD.9.31%233 930
ROCHE HOLDING10.86%233 930
MERCK AND COMPANY6.78%208 546